S100B has pleiotropic effects on vaso-occlusive manifestations in sickle cell disease

Xu Zhang; Binal N. Shah; Wei Zhang; Santosh L. Saraf; Mehdi Nouraie; Sergei Nekhai; Roberto F. Machado; Mark T. Gladwin; Victor R. Gordeuk

doi:10.1002/ajh.25691

S100B has pleiotropic effects on vaso-occlusive manifestations in sickle cell disease

Xu Zhang^*, Binal N. Shah, Wei Zhang, Santosh L. Saraf, Mehdi Nouraie, Sergei Nekhai, Roberto F. Machado, Mark T. Gladwin, Victor R. Gordeuk

^*Corresponding author for this work

Preventive Medicine

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	E62-E65
Journal	American Journal of Hematology
Volume	95
Issue number	3
DOIs	https://doi.org/10.1002/ajh.25691
State	Published - Mar 1 2020

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.25691

Cite this

@article{0faf961550a748ce8104dcfea362dd44,

title = "S100B has pleiotropic effects on vaso-occlusive manifestations in sickle cell disease",

author = "Xu Zhang and Shah, {Binal N.} and Wei Zhang and Saraf, {Santosh L.} and Mehdi Nouraie and Sergei Nekhai and Machado, {Roberto F.} and Gladwin, {Mark T.} and Gordeuk, {Victor R.}",

note = "Funding Information: This work is supported in part by grants R01 HL079912-04, 2 R25-HL03679-08, and 1P30HL107253 (V.R.G.); 1P50HL118006 (S.N.); R01HL111656 and R01HL127342 (R.F.M.); K23HL125984 (S.L.S); UL1TR000050 (UIC Center for Clinical and Translational Science). We thank UI Health Biorepository for preparing serum for ELISA experiment. The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C). The authors thank the staff and participants of the ARIC study for their important contributions. Funding for GENEVA was provided by National Human Genome Research Institute grant U01HG004402 (E. Boerwinkle). The Jackson Heart Study is supported by contracts HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201300049C, HHSN268201300050C from the National Heart, Lung, and Blood Institute and the National Institute on Minority Health and Health Disparities. Phenotype data have been collected as described in PMID: 16320381 and at https://www.jacksonheartstudy.org/jhsinfo/. Authorized access to genotype data may be obtained through accession numbers phs000286.v4.p1 (JHS parent study), phs000402 (HeartGO_JHS), phs000498 (JHS_AllelicSpectrum_Seq), and phs000499 (JHS_CARe). Funding for CARe genotyping was provided by NHLBI Contract N01-HC-65226. The Cardiovascular Health Study research reported in this article was supported by contract numbers N01-HC85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC85084, N01-HC-85085, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC55222, N01-HC-75150, N01-HC-45133, N01-HC-85239 and HHSN268201200036C; grant numbers U01 HL080295 from the National Heart, Lung, and Blood Institute and R01 AG-023629 from the National Institute on Aging, with additional contribution from the National Institute of Neurological Disorders and Stroke. A full list of principal CHS investigators and institutions can be found at https://chs-nhlbi.org/pi. This manuscript was not prepared in collaboration with CHS investigators and does not necessarily reflect the opinions or views of CHS, or the NHLBI. Support for the Cardiovascular Health Study Whole Genome Study was provided by NHLBI grant HL087652. Additional support for infrastructure was provided by HL105756 and additional genotyping among the African-American cohort was supported in part by HL085251. The DNA handling and genotyping at Cedars-Sinai Medical Center was supported in part by National Center for Research Resources grant UL1RR033176, now at the National Center for Advancing Translational Technologies CTSI grant UL1TR000124; in addition to the National Institute of Diabetes and Digestive and Kidney Diseases grant DK063491 to the Southern California Diabetes Endocrinology Research Center. Funding Information: This work is supported in part by grants R01 HL079912‐04, 2 R25‐HL03679‐08, and 1P30HL107253 (V.R.G.); 1P50HL118006 (S.N.); R01HL111656 and R01HL127342 (R.F.M.); K23HL125984 (S.L.S); UL1TR000050 (UIC Center for Clinical and Translational Science). We thank UI Health Biorepository for preparing serum for ELISA experiment. The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C). The authors thank the staff and participants of the ARIC study for their important contributions. Funding for GENEVA was provided by National Human Genome Research Institute grant U01HG004402 (E. Boerwinkle). The Jackson Heart Study is supported by contracts HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201300049C, HHSN268201300050C from the National Heart, Lung, and Blood Institute and the National Institute on Minority Health and Health Disparities. Phenotype data have been collected as described in PMID: 16320381 and at https://www.jacksonheartstudy.org/jhsinfo/ . Authorized access to genotype data may be obtained through accession numbers phs000286.v4.p1 (JHS parent study), phs000402 (HeartGO_JHS), phs000498 (JHS_AllelicSpectrum_Seq), and phs000499 (JHS_CARe). Funding for CARe genotyping was provided by NHLBI Contract N01‐HC‐65226. The Cardiovascular Health Study research reported in this article was supported by contract numbers N01‐HC85079, N01‐HC‐85080, N01‐HC‐85081, N01‐HC‐85082, N01‐HC‐85083, N01‐HC85084, N01‐HC‐85085, N01‐HC‐85086, N01‐HC‐35129, N01 HC‐15103, N01 HC55222, N01‐HC‐75150, N01‐HC‐45133, N01‐HC‐85239 and HHSN268201200036C; grant numbers U01 HL080295 from the National Heart, Lung, and Blood Institute and R01 AG‐023629 from the National Institute on Aging, with additional contribution from the National Institute of Neurological Disorders and Stroke. A full list of principal CHS investigators and institutions can be found at https://chs-nhlbi.org/pi . This manuscript was not prepared in collaboration with CHS investigators and does not necessarily reflect the opinions or views of CHS, or the NHLBI. Support for the Cardiovascular Health Study Whole Genome Study was provided by NHLBI grant HL087652. Additional support for infrastructure was provided by HL105756 and additional genotyping among the African‐American cohort was supported in part by HL085251. The DNA handling and genotyping at Cedars‐Sinai Medical Center was supported in part by National Center for Research Resources grant UL1RR033176, now at the National Center for Advancing Translational Technologies CTSI grant UL1TR000124; in addition to the National Institute of Diabetes and Digestive and Kidney Diseases grant DK063491 to the Southern California Diabetes Endocrinology Research Center. ",

year = "2020",

month = mar,

day = "1",

doi = "10.1002/ajh.25691",

language = "English (US)",

volume = "95",

pages = "E62--E65",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "3",

}

TY - JOUR

T1 - S100B has pleiotropic effects on vaso-occlusive manifestations in sickle cell disease

AU - Zhang, Xu

AU - Shah, Binal N.

AU - Zhang, Wei

AU - Saraf, Santosh L.

AU - Nouraie, Mehdi

AU - Nekhai, Sergei

AU - Machado, Roberto F.

AU - Gladwin, Mark T.

AU - Gordeuk, Victor R.

N1 - Funding Information: This work is supported in part by grants R01 HL079912-04, 2 R25-HL03679-08, and 1P30HL107253 (V.R.G.); 1P50HL118006 (S.N.); R01HL111656 and R01HL127342 (R.F.M.); K23HL125984 (S.L.S); UL1TR000050 (UIC Center for Clinical and Translational Science). We thank UI Health Biorepository for preparing serum for ELISA experiment. The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C). The authors thank the staff and participants of the ARIC study for their important contributions. Funding for GENEVA was provided by National Human Genome Research Institute grant U01HG004402 (E. Boerwinkle). The Jackson Heart Study is supported by contracts HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201300049C, HHSN268201300050C from the National Heart, Lung, and Blood Institute and the National Institute on Minority Health and Health Disparities. Phenotype data have been collected as described in PMID: 16320381 and at https://www.jacksonheartstudy.org/jhsinfo/. Authorized access to genotype data may be obtained through accession numbers phs000286.v4.p1 (JHS parent study), phs000402 (HeartGO_JHS), phs000498 (JHS_AllelicSpectrum_Seq), and phs000499 (JHS_CARe). Funding for CARe genotyping was provided by NHLBI Contract N01-HC-65226. The Cardiovascular Health Study research reported in this article was supported by contract numbers N01-HC85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC85084, N01-HC-85085, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC55222, N01-HC-75150, N01-HC-45133, N01-HC-85239 and HHSN268201200036C; grant numbers U01 HL080295 from the National Heart, Lung, and Blood Institute and R01 AG-023629 from the National Institute on Aging, with additional contribution from the National Institute of Neurological Disorders and Stroke. A full list of principal CHS investigators and institutions can be found at https://chs-nhlbi.org/pi. This manuscript was not prepared in collaboration with CHS investigators and does not necessarily reflect the opinions or views of CHS, or the NHLBI. Support for the Cardiovascular Health Study Whole Genome Study was provided by NHLBI grant HL087652. Additional support for infrastructure was provided by HL105756 and additional genotyping among the African-American cohort was supported in part by HL085251. The DNA handling and genotyping at Cedars-Sinai Medical Center was supported in part by National Center for Research Resources grant UL1RR033176, now at the National Center for Advancing Translational Technologies CTSI grant UL1TR000124; in addition to the National Institute of Diabetes and Digestive and Kidney Diseases grant DK063491 to the Southern California Diabetes Endocrinology Research Center. Funding Information: This work is supported in part by grants R01 HL079912‐04, 2 R25‐HL03679‐08, and 1P30HL107253 (V.R.G.); 1P50HL118006 (S.N.); R01HL111656 and R01HL127342 (R.F.M.); K23HL125984 (S.L.S); UL1TR000050 (UIC Center for Clinical and Translational Science). We thank UI Health Biorepository for preparing serum for ELISA experiment. The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C). The authors thank the staff and participants of the ARIC study for their important contributions. Funding for GENEVA was provided by National Human Genome Research Institute grant U01HG004402 (E. Boerwinkle). The Jackson Heart Study is supported by contracts HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201300049C, HHSN268201300050C from the National Heart, Lung, and Blood Institute and the National Institute on Minority Health and Health Disparities. Phenotype data have been collected as described in PMID: 16320381 and at https://www.jacksonheartstudy.org/jhsinfo/ . Authorized access to genotype data may be obtained through accession numbers phs000286.v4.p1 (JHS parent study), phs000402 (HeartGO_JHS), phs000498 (JHS_AllelicSpectrum_Seq), and phs000499 (JHS_CARe). Funding for CARe genotyping was provided by NHLBI Contract N01‐HC‐65226. The Cardiovascular Health Study research reported in this article was supported by contract numbers N01‐HC85079, N01‐HC‐85080, N01‐HC‐85081, N01‐HC‐85082, N01‐HC‐85083, N01‐HC85084, N01‐HC‐85085, N01‐HC‐85086, N01‐HC‐35129, N01 HC‐15103, N01 HC55222, N01‐HC‐75150, N01‐HC‐45133, N01‐HC‐85239 and HHSN268201200036C; grant numbers U01 HL080295 from the National Heart, Lung, and Blood Institute and R01 AG‐023629 from the National Institute on Aging, with additional contribution from the National Institute of Neurological Disorders and Stroke. A full list of principal CHS investigators and institutions can be found at https://chs-nhlbi.org/pi . This manuscript was not prepared in collaboration with CHS investigators and does not necessarily reflect the opinions or views of CHS, or the NHLBI. Support for the Cardiovascular Health Study Whole Genome Study was provided by NHLBI grant HL087652. Additional support for infrastructure was provided by HL105756 and additional genotyping among the African‐American cohort was supported in part by HL085251. The DNA handling and genotyping at Cedars‐Sinai Medical Center was supported in part by National Center for Research Resources grant UL1RR033176, now at the National Center for Advancing Translational Technologies CTSI grant UL1TR000124; in addition to the National Institute of Diabetes and Digestive and Kidney Diseases grant DK063491 to the Southern California Diabetes Endocrinology Research Center.

PY - 2020/3/1

Y1 - 2020/3/1

UR - http://www.scopus.com/inward/record.url?scp=85077906172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077906172&partnerID=8YFLogxK

U2 - 10.1002/ajh.25691

DO - 10.1002/ajh.25691

M3 - Letter

C2 - 31805207

AN - SCOPUS:85077906172

SN - 0361-8609

VL - 95

SP - E62-E65

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 3

ER -

S100B has pleiotropic effects on vaso-occlusive manifestations in sickle cell disease

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this